Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

January 2020 Approvals: Medtronic And Abbott Announce DBS Approvals

Executive Summary

January’s new medical device approvals include the US FDA approval of a new indication for Abbott’s Infinity deep brain stimulation system and a CE mark for Abbott’s Tendyne transcatheter mitral valve replacement system. Medtronic also announced CE marks for a new line of implantable defibrillators and resynchronization devices as well as a CE mark for its Percept PC neurostimulator.

You may also be interested in...



Cardiovascular Sales & Earnings Roundup: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019

The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.

Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark

Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.

HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data

Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT126209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel